Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
Continue Reading
-
Noosa News13 hours agoWilliam Robinson dies aged 89
-
Business17 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News14 hours agoAFL live updates: Gold Coast vs Essendon – blog, scores and stats
-
Noosa News14 hours agoTwo-time Archibald Prize-winning painter William Robinson has died, aged 89